About this trial
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Advanced /metastatic colorectal tumors that have failed standard treatments
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1
Adequate organ function based on laboratory testing
Disqualifiers
Active infection with hepatitis B or C
Uncontrolled CNS metastases
Active autoimmune disease
Clinically significant cardiovascular disease not adequately controlled with medication or impaired function
Trial design
Sequential
Treatments tested in this trial
LTZ-232
DrugLTZ-232 will be administered intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met.
Treatment groups
Trial outcomes
Primary outcomes
Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.
To determine the incidence, severity, and type of adverse events according to NCI and CTCAE v5.0 and assessment of protocol defined dose limiting toxicity criteria.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.